Chardan analyst Daniil Gataulin initiated coverage of Annexon (ANNX) with a Buy rating and $16 price target The firm cites the commercial potential of the company’s complement C1q inhibitors tanruprubart in Guillain-Barre syndrome and vonaprument in geographic atrophy for the Buy rating. It sees additional upside potential from tanruprubart in Huntington’s disease.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX: